Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Carsten Denkert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2249-0982; OpenAlex author ID A5033698551. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers

Papers 15

  1. BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells. Co-author DOI 10.1038/s41423-024-01195-1↗
  2. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331854↗
  3. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
  4. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Last author DOI 10.1158/1078-0432.ccr-19-3034↗
  5. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-018-0093-y↗
  6. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  7. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.016↗
  8. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.034↗
  9. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Co-author DOI 10.1016/j.prp.2016.06.001↗
  10. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… Co-author DOI 10.1016/j.ejca.2015.05.005↗
  11. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. First author DOI 10.1038/bjc.2014.495↗
  12. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Last author DOI 10.1093/annonc/mdu084↗
  13. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000077↗
  14. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. Co-author DOI 10.1002/jso.23409↗
  15. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Last author DOI 10.1111/j.1365-2559.2012.04225.x↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marcus Bahra · 12 shared papers, 2012–2021 · strength 0.66
  2. Jana Käthe Striefler · 11 shared papers, 2012–2021 · strength 0.60
  3. Bruno Valentin Sinn · 11 shared papers, 2012–2021 · strength 0.60
  4. Hanno B. Riess · 11 shared papers, 2012–2021 · strength 0.60
  5. Marianne Sinn · 10 shared papers, 2013–2021 · strength 0.58
  6. Uwe Pelzer · 9 shared papers, 2013–2021 · strength 0.54
  7. Helmut Oettle · 9 shared papers, 2013–2021 · strength 0.54
  8. Philipp Lohneis · 8 shared papers, 2014–2021 · strength 0.51
  9. Anna I. Brichkina · 2 shared papers, 2024 · strength 0.31
  10. Corinna Ulrike Keber · 2 shared papers, 2024 · strength 0.31
  11. Matthias Lauth · 2 shared papers, 2024 · strength 0.31
  12. Jens Stieler · 5 shared papers, 2013–2015 · strength 0.19
  13. Wilko Weichert · 4 shared papers, 2012–2018 · strength 0.19
  14. Anja Jühling · 3 shared papers, 2016–2018 · strength 0.18
  15. Felix S.R. Picard · 1 shared paper, 2024 · strength 0.16
  16. Magdalena Huber · 1 shared paper, 2024 · strength 0.16
  17. Veronika Lutz · 1 shared paper, 2024 · strength 0.16
  18. Detlef Klaus Bartsch · 1 shared paper, 2024 · strength 0.16
  19. Thomas Mathias Gress · 1 shared paper, 2024 · strength 0.16
  20. Frederick Klauschen · 3 shared papers, 2012–2020 · strength 0.15
  21. Malte Buchholz · 1 shared paper, 2024 · strength 0.15
  22. Viviane Ponath · 1 shared paper, 2024 · strength 0.15
  23. Bilal Alashkar Alhamwe · 1 shared paper, 2024 · strength 0.15
  24. Elke Pogge von Strandmann · 1 shared paper, 2024 · strength 0.15
  25. Anna Melissa Schlitter · 2 shared papers, 2017–2018 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.